Investigator Manual Revised August 19, 2013
|
|
- Abner Horn
- 6 years ago
- Views:
Transcription
1 Investigator Manual Revised August 19, 2013
2 Investigator Manual Page 2 of 31 Table of Contents What is the purpose of this manual?... 3 What is Human Research?... 3 What is the Human Research Protection Program?... 3 What training does my staff and I need to conduct Human Research?... 3 How do I submit new Human Research to the IRB?... 4 How do I complete the FORM HRP-211: Application for Human Research?... 4 How do I write a protocol using the MSSM template?... 7 How do I activate a protocol at a new MSSM site if it has already been approved by the MSSM IRB for another site?... 8 How do I create a consent document?... 8 What are the different regulatory classifications that research activities may fall under?... 9 What are the decisions an IRB can make when reviewing a protocol?... 9 How does the IRB decide whether to approve Human Research? What will happen after IRB review? What are my obligations after IRB approval? How do I document consent? How do I submit a modification? How do I submit for a continuing review? How do I close out a study? How long do I keep records? What if I need to use an unapproved drug or device in a life-threatening situation and there is no time for prior IRB review? How do I get additional information and answers to questions? Appendix A-1 Additional Requirements for DHHS-Regulated Research Appendix A-2 Additional Requirements for FDA-Regulated Research Appendix A-3 Additional Requirements for Clinical Trials (ICH-GCP) Appendix A-4 Additional Requirements for Department of Defense (DOD) research Appendix A-5 Additional Requirements for Department of Navy (DON) Research Appendix A-6 Additional Requirements for Department of Energy (DOE) Research Appendix A-7 Additional Requirements for Department of Education (ED) Research... 31
3 Investigator Manual Page 3 of 31 What is the purpose of this manual? The Investigator Manual is designed to guide you through policies and procedures related to the conduct of Human Research that are specific to this organization. General information regarding Human Research protections and relevant federal regulations and guidance is incorporated into the required human protections training. For additional information, see below: What training does my staff and I need in order to conduct Human Research? What is Human Research? An algorithm for determining whether an activity is Human Research can be found in the WORKSHEET HRP-309: Human Research Determination, located on the PPHS website. Use this document for guidance as to whether an activity meets either the DHHS or FDA definition of Human Research, keeping in mind that the PPHS makes the ultimate determination in questionable cases as to whether an activity constitutes Human Research subject to IRB oversight. You are responsible not to conduct Human Research without prior PPHS review and approval. If you have questions about whether an activity is Human Research, contact the PPHS office who will provide you with a determination. If you wish to have a written determination, provide a written request to the PPHS office. The document HRP-101: HUMAN RESEARCH PROTECTION PROGRAM PLAN defines the activities that this organization considers to be Human Research as defined in DHHS regulations at 45 CFR (d) and 45 CFR (f) and as defined in FDA regulations at 21 CFR (c), 21 CFR (e), and 21 CFR 812.3(p). What is the Human Research Protection Program? The document HRP-101: HUMAN RESEARCH PROTECTION PROGRAM PLAN describes this organization s overall plan to protect subjects in Human Research. The mission of the Human Research Protection Program. The ethical principles that the organization follows governing the conduct of Human Research. The applicable laws that govern Human Research. When the organization becomes engaged in Human Research and when someone is acting as an agent of the organization conducting Human Research. The types of Human Research that may not be conducted. The roles and responsibilities of individuals within the organization. What training does my staff and I need to conduct Human Research? Investigators and staff will be required to complete the online Collaborative Institutional Training Initiative (CITI) human subjects protection online training program. The CITI site can be accessed at This training is valid for 3 years, after which time a refresher CITI course or additional training must be completed. Further information on this training requirement and others will be available on the PPHS website.
4 Investigator Manual Page 4 of 31 Investigators and staff who are involved in FDA-regulated research will also be required to complete either the online Collaborative Institutional Training Initiative (CITI) Good Clinical Practice (GCP) course, or the Mount Sinai Research Compliance department s Clinical Research: Are You Doing It Right? course. Please note that all members of the research team involved in design, conduct, or reporting of the research are required to complete this training. IRB approval will not be granted for protocols in which members of the research team have not completed human research protections training. How do I submit new Human Research to the IRB? Complete the FORM HRP-211: Application for Human Research, attach all requested documents per the instructions, obtain all required signatures, and provide the requested number of copies to the PPHS office. Maintain electronic copies of all information submitted to the PPHS. How do I complete the FORM HRP-211: Application for Human Research? Form Header (Basic Protocol Information) 1) Protocol Name Enter the full protocol name and, where applicable, the protocol code or number in parentheses (such as a cooperative group or sponsored protocol). 2) Principal Investigator Name the person with overall responsibility for the conduct of the Human Research. There can be only one investigator with this overall responsibility. If the PI is new to the institution or the PPHS application process, or if there has been a change in the PI s contact information, include that information within the other submission materials. 3) Primary Contact Name Name the person who will receive a copy of all communications in addition to the principal investigator. Leave blank if there is no contact other than the principal investigator. There can only be one contact. If this person is new to institution or the PPHS application process, or if there has been a change in their contact information, mention that within the other submission materials. 4) Contact Info Provide that person s and direct phone number in the area provided. 5) Date Revised Provide the date that the application form is being filled out. 6) Study Number Provide the study number when known. It may not be known at time of initial submission. Section A: Elements of the Research Check each applicable item to indicate whether the Human Research involves the following and complete the associated forms:
5 Investigator Manual Page 5 of 31 a) Use of any external (i.e. non-mssm) sites at which Human Research activities will be conducted For example, if you are conducting research in a school, nursing home, or other external facility or site, list it here. Research affiliates such as the Queens Hospital Network, Elmhurst Hospital Network, Jewish Home and Hospital, and Bronx VA are considered external sites. b) Use of drugs other than the use of approved drugs in the course of medical practice c) Use of a device to evaluate its safety or effectiveness d) Use of a HUD to evaluate its safety or effectiveness e) Submission of a protocol already approved by the MSSM IRB under a different principal investigator. Your intention is to activate the same protocol at a different site(s) for which you are taking separate and full responsibility. Section B: Approvals Required Prior to Initiating Research Check all additional approvals that are required: a) Radiation being used for reasons other than clinical care b) Use of materials requiring approval from the Institutional Biosafety Committee. This would include biohazards, toxins, infectious agents (of biological origin or otherwise), recombinant DNA, etc. Check the IBC website for materials that require IBC submission and approval. c) Cancer research that requires approval from the Protocol Monitoring & Review Committee. Check with the PR&MC for the kinds of projects that require PR&MC submission and approval. d) Investigators or research staff with a significant financial conflict of interest in the research. Refer to the FCOIR website or committee for definitions, disclosure requirements, and management plans (if applicable). e) Pathological specimens that require approval from the Pathology department. Check with the Department of Pathology for materials that require submission and approval. f) Human embryonic stem cells. Check with the ESCRO committee for materials that require ESCRO submission and approval. g) Study of use/outcomes for a product sold to Mount Sinai at full price and sponsored by entity with economic interest in sale of product. Check with the Registry Committee for additional information regarding their review and approval process. h) Submission required by the Grants and Contracts Office. Check with the GCO regarding their submission requirements i) Submission required by the Clinical Trials Budget and Billing Compliance (CTBB). Check with the Office of Clinical Research (OCR) regarding their CTBB checklist, submission requirements, coverage analysis (MCA) and approvals. Section C: Funding Sources List all funding sources. For each, list the associated grant number and Infoed/GCO ID#, if known. Note: modifying funding sources requires that you inform GCO and make appropriate FCOIR disclosures. Section D: Reserved
6 Investigator Manual Page 6 of 31 Section E: Names of all research personnel involved in the design, conduct, or reporting of the research List all Human Research personnel involved in the design, conduct, or reporting of the Human Research and their roles. This includes all co-investigators, sub-investigators, coordinators, assistants, students, and collaborators who have a role in the design, conduct, or reporting of the Human Research. Indicate each person s department(s). If personnel have multiple department appointments, list the department that may be related to the topic of this research first. Indicate each person s role in the research. If this person is new to institution or the PPHS application process, or if there has been a change in their contact information, submit that information with the other submission materials. Check the box if the person will have contact with subjects or access to private identifiable data and whether the person will be involved in the consent process. Check the box if the person has fulfilled their PPHS education requirements. The research will not be approved if all individuals have not completed the requirements. Further information regarding the requirements is available in the What training does my staff and I need to conduct Human Research? section of this document. Indicate the location of evidence of qualifications. The location may vary by role in the research. Typically investigators submit a copy of their CV or biosketch, and others provide a resume or a summary description of their qualifications. Indicate whether the person has a significant financial interest related to the Human Research. The definition of significant financial interest related to the Human Research is included on the application and in the institutional Financial Conflict of Interest in Research policies. Section F: Other Documents Provide the requested copies of additional documents. Section G: Principal Investigator signature Personally sign and date the application. Section H: Departmental/Designee Approval Have your department chair or their official designee sign and date the application. Follow any departmental procedures that are required in order to obtain their approval. This signature is in addition to signatures obtained for other institutional requirements (such as GCO submissions). Note: if the research involves personnel from multiple departments, the Chair of each department represented must sign and date the application. A standalone document HRP-211h: Application for Human Research Standalone Chair Signoff Section is available on the PPHS website for this purpose.
7 Investigator Manual Page 7 of 31 Note: if facilities/resources are required for this Human Research which the listed personnel do not have formal authority to provide (e.g. radiology scanning time), it is the PI s responsibility to obtain permission for these resources prior to the PPHS submission to assure the feasibility of the Human Research. Appendix A: External Site Approvals If applicable, list any non-mssm study sites/facilities in which human research activities will be conducted, and provide a contact name and contact information for each site. Indicate whether an authorized representative of the site has granted permission for you to conduct the Human Research and provide evidence of this permission when available. Indicate if the site s IRB will review the Human Research (answer No if the site does not have an IRB). Answer whether the site will request to rely on our IRBs, or another IRB. Research affiliates such as the Queens Hospital Network, Elmhurst Hospital Network, Jewish Home and Hospital, and Bronx VA are considered external sites. Appendix B: Drugs/Biologics Complete Appendix B for the drug(s) or biologic(s) being used in the Human Research (FDA approved and unapproved). This form does not need to be completed for FDA-approved drugs or biologics whose use in a protocol is totally up to the discretion of an attending physician (not specifically prescribed by the protocol.) Each Appendix B form needs to be signed by the Research Pharmacy. Follow Research Pharmacy policy regarding their submission requirements. Appendix C: Devices Complete one Appendix C form for each device being evaluated for safety or effectiveness (approved and unapproved). Please obtain any necessary departmental approvals for device use/storage prior to the submission to the PPHS. How do I write a protocol using the MSSM template? Use the HRP-503a: Template Protocol and accompanying HRP-503: Template Protocol Instructions as a starting point for drafting a new protocol, and reference the instructions in italic text for the information the PPHS looks for when reviewing protocols. Here are some key points to remember when developing a protocol: The italicized bullet points in the HRP-503: Template Protocol Instructions serve as guidance to investigators when developing a Human Research Protocols for submission to the PPHS. All italicized comments are meant to be deleted prior to submission. For any items described in a sponsor s protocol or other documents submitted with the application, investigators may simply reference the page numbers of these documents within the protocol template rather than repeat information. When writing a protocol, always keep an electronic copy. You will need to modify this copy when making changes to the protocol. If you believe your activity may not be Human Research, contact the PPHS office prior to developing your protocol. Note that, depending on the nature of your research, certain sections of the protocol template may not be applicable. Indicate this as appropriate by marking N/A after each section heading.
8 Investigator Manual Page 8 of 31 How do I activate a protocol at a new MSSM site if it has already been approved by the MSSM IRB for another site? In some cases (e.g. multi-site drug trials), the same protocol may be submitted to the IRB by separate principal investigators for separate sites under MSSM jurisdiction. If you are trying to activate a protocol at a new site/sites for which you will serve as the principal investigator, and the MSSM IRB has already approved the protocol for another principal investigator at another site, you may develop and submit a protocol that omits the following sections from the Human Research Protocol template: Objectives Background Inclusion and Exclusion Criteria Study Timelines Study Endpoints Procedures Involved in the Human Research Specimen Banking Data Management and Confidentiality Provisions to Monitor the Data to Ensure the Safety of Subjects Withdrawal of Subjects Risks to Subjects Provisions for Research Related Injury Potential Benefits to Subjects Multi-Site Human Research (Coordinating Center) Complete the Human Research Protocol template by describing information specific to the site(s) for which you will serve as Principal Investigator. Do not repeat information in the approved protocol that applies to all site(s). When submitting the Application for Human Research form and the additional required appendices and documents, you may omit the following when they exist: Evaluation instruments and surveys Grant application Complete sponsor protocol including DHHS-approved protocol (e.g., an NIH-sponsored Cooperative Group Clinical Trial protocol) DHHS-approved sample consent document ((e.g., sample consent from an NIH-sponsored Cooperative Group Clinical Trial) Current investigator brochure for each investigational drug Current package insert for each marketed drug Current product information for each investigational device If the research is conducted or funded by the Department of Energy, a completed Checklist for IRBs to Use in Verifying that HS Research Protocols are In Compliance with DOE Requirements How do I create a consent document? Use the HRP-502 TEMPLATE CONSENT DOCUMENT to create a consent document.
9 Investigator Manual Page 9 of 31 Note that all consent documents must contain all of the required and all additional appropriate elements of informed consent disclosure. Review section 7 of the PPHS s WORKSHEET HRP-311: Criteria for Approval and Additional Considerations, to ensure that these elements are addressed. We require that you date the revisions of your consent documents to ensure that you use the most recent version approved by the IRB with prospective subjects, and to fulfill your researcher record-keeping responsibilities. What are the different regulatory classifications that research activities may fall under? Submitted activities may fall under one of the following four regulatory classifications: Not Human Research : Activities must meet the DHHS or FDA definition of research involving human subjects for the activity to fall under PPHS oversight. Activities that meet neither definition of research nor human Subjects are not subject to PPHS oversight or review. Review the PPHS office s WORKSHEET HRP-309: Human Research Determination for reference. Contact the PPHS office in cases where it is unclear whether an activity meets the regulatory definition of Human Research. Exempt: Certain categories of Human Research may be exempt from regulation applicability but still require review and a determination made by someone other than the investigator. Review the PPHS s WORKSHEET: Exemption Determination for reference on the categories of research that may be exempt. If your department has a PPHS-certified Exempt Determiner, that individual is authorized to provide an unofficial exemption determination. Official exempt determinations can only be made by the PPHS office (official determination may be required by an external funder or journal). Review Using the Expedited Procedure: Certain categories of non-exempt Human Research may qualify for review that does not require convened IRB review (called an expedited procedure). Review the PPHS s CHECKLIST HRP-413: Eligibility for Review Using the Expedited Procedure for reference on the categories of research that may be reviewed using the expedited procedure. Review by the Convened IRB: Non-Exempt Human Research that does not qualify for review using the expedited procedure must be reviewed by the convened IRB. What are the decisions an IRB can make when reviewing a protocol? An IRB may approve research, require modifications to secure approval, table research, or disapprove research: Approval: Made when all criteria for approval are met. See How does the IRB decide whether to approve Human Research? below. Response to PPHS Required to Secure Approval: Made when IRB members require specific affirmations or modifications to a protocol before approval can be finalized. Response to PPHS Required to Determine Not Human Subject Research: Made when specific affirmations or modifications to a protocol are required before a determination that a protocol does not involve human subject research can be finalized.
10 Investigator Manual Page 10 of 31 Tabled: Made when the IRB cannot approve the research at a meeting for reasons unrelated to the protocol, such as loss of quorum. When taking this action, the IRB automatically schedules the protocol for a subsequent meeting. Deferred: Made when the IRB determines that the board is unable to approve a protocol and the IRB suggests modifications the might make the research approvable. When making this motion, the IRB describes its reasons for this decision, describes modifications that might make the research approvable, and gives the investigator an opportunity to respond to the IRB in person or in writing. Disapproval: Made when the IRB determines that it is unable to approve a protocol and the IRB cannot describe modifications the might make the research approvable. When making this motion, the IRB describes its reasons for this decision and gives the investigator an opportunity to respond to the IRB in person or in writing. How does the IRB decide whether to approve Human Research? The criteria for IRB approval can be found in the WORKSHEET: Exemption Determination for exempt Human Research and the CHECKLIST HRP-311: Criteria for Approval and Additional Considerations for non-exempt Human Research. The latter checklists reference other checklists that might be relevant. All checklists can be found on the IRB Web site. These checklists are used for initial review, continuing review, and review of modifications to previously approved Human Research. You are encouraged to use the checklists to write your protocol in a way that addresses the criteria for approval. What will happen after IRB review? The IRB will provide you with a written decision indicating that the IRB has approved the Human Research, requires modifications to secure approval, or has disapproved the Human Research. If the IRB has approved the Human Research: The Human Research may commence once all other organizational approvals have been met. IRB approval for non-exempt research is good for a limited period of time, as noted in the approval letter. If the IRB requires a response to secure approval and you are agreeable to the modifications or confirmations required, make the requested modifications or confirmations and submit them to the IRB within 30 days using FORM HRP-214: Response to PPHS If all requested modifications or confirmations are made, the IRB will issue a final approval. Research cannot commence until this final approval is received. If you do not respond to the IRB within 30 days, the offer of approval with the requested responses will be withdrawn. If you do not accept the requested modifications or confirmations, write up your response and submit it to the IRB within 30 days. If you do not provided additional information or correspondence within 30 days, the IRB will require a complete new protocol submission. If the IRB requires a response to determine that a protocol is not human subject research, and you are agreeable to the modifications or confirmations required, make the requested modifications or confirmations and submit them to the IRB within 30 days. You may find using FORM HRP-214: Response to PPHS helpful. If all requested modifications or confirmations are made, the IRB
11 Investigator Manual Page 11 of 31 will issue a final determination. Research cannot commence until this final determination is received. If you do not respond to the IRB within 30 days, the offer of determination given the requested responses will be withdrawn. If you do not accept the requested modifications or confirmations, write up your response and submit it to the IRB within 30 days. If you do not provided additional information or correspondence within 30 days, the IRB will require a complete new protocol submission. If the IRB defers the Human Research: The IRB will provide a statement of the reasons for deferral and may provide suggestions on how to make the study approvable, and will give you an opportunity to respond in writing. In most cases if the IRB s reasons for the deferral are addressed by a subsequent modification, the Human Research can be approved. You may submit a response to the IRB using FORM HRP-214: Response to PPHS. If the IRB disapproves the Human Research: The IRB will provide a statement of the reasons for disapproval and give you an opportunity to respond in writing. In all cases, you have the right to request to address your concerns to the IRB directly at an IRB meeting. What are my obligations after IRB approval? 1) Do not start Human Research activities until you have the final IRB approval letter. NOTE: If you are in receipt of an approved pending funding letter from the IRB, you must take the required action stipulated in the letter before you will receive the final IRB approval letter and be able to begin any Human Research activities. 2) Personally conduct or supervise the Human Research. a) Conduct the Human Research in accordance with the relevant current protocol as approved by the IRB. b) When required by the IRB ensure that consent or permission is obtained in accordance with the relevant current protocol as approved by the IRB. c) Do not modify the Human Research without prior IRB review and approval unless necessary to eliminate apparent immediate hazards to subjects. i) Report any changes in approved research initiated without prior IRB approval to eliminate apparent immediate hazards to subjects promptly (within 5 days) to the IRB using FORM HRP-224: Reportable New Information ii) The IRB will review this information to determine whether each change was consistent with ensuring the subject s continued welfare d) Protect the rights, safety, and welfare of subjects involved in the research. 3) Submit to the IRB: a) Proposed modifications as described in this manual. (See How do I submit a modification? ) b) A continuing review application as requested in the approval letter and as described in this manual. (See How do I submit continuing review? c) A final review application when the Human Research is closed. (See How Do I Close Out a Study? ) 4) Report any of the information items on the FORM HRP-224: Reportable New Information to the IRB within five business days. 5) Do not accept or provide payments to professionals in exchange for referrals of potential subjects ( finder s fees. ) 6) Do not accept payments designed to accelerate recruitment that were tied to the rate or timing of enrollment ( bonus payments. )
12 Investigator Manual Page 12 of 31 7) Maintain signed and dated consent documents for three years after completion of the research. Maintain signed and dated HIPAA authorizations and consent documents that include HIPAA authorizations for six years after completion of the research. 8) See additional requirements of various federal agencies in Appendix A of this document. How do I document consent? The document HRP SOP - Written Documentation of Consent, establishes the process to document the informed consent process in writing. Use the signature block approved by the IRB on the consent document. Complete all items in the signature block, including dates and applicable checklists. The following are some requirements for consent documentation: The subject or representative signs and dates the consent document. The individual obtaining consent signs and dates the consent document. Whenever required by the IRB, the subject s or representative s signature is to be witnessed by an individual who signs and dates the consent document. For subjects who cannot read, and whenever required by the IRB or the study sponsor, a witness to the oral presentation signs and dates the consent document. A copy of the signed and dated consent document is to be provided to the subject. For subjects who cannot provide a signature, refer to the procedures in HRP SOP - Written Documentation of Consent. How do I submit a modification? Complete the FORM HRP-213: Modification of Approved Human Research, attach all requested supplements, have the formed signed by the individuals listed in the form, and provide the requested number of copies to the PPHS office. Maintain electronic copies of all information submitted to the IRB. Please note that research must continue to be conducted without inclusion of the modification until IRB approval is received. If the research is determined to be exempt, and a proposed modification affects the design and conduct of the research in the approved protocol (including the subjects, sources, or mechanisms of data/material collection), complete the FORM HRP-213: Modification of Approved Human Research, attach all requested supplements, and provide the requested number of copies to the PPHS office How do I submit for a continuing review? Complete the FORM HRP-212: Continuing/Final Review Progress Report, attach all requested supplements, have the formed signed by the individuals listed in the form, and provide the requested number of copies to the PPHS office. Maintain electronic copies of all information submitted to the IRB. If the continuing review involves modifications to previously approved research, submit those modifications as a separate request for modification using the FORM HRP-213: Modification of Approved Human Research. If the continuing review application is not received by the date requested in the approval letter, you will be restricted from submitting new Human Research until the completed application has been received.
13 Investigator Manual Page 13 of 31 If the approval of Human Research expires all Human Research procedures related to the protocol under review must cease, including recruitment, advertisement, screening, enrollment, consent, interventions, interactions, and collection of private identifiable information. Continuing Human Research procedures is a violation of federal regulations. If current subjects will be harmed by stopping Human Research procedures that are available outside the Human Research context, provide these on a clinical basis as needed to protect current subjects. If current subjects will be harmed by stopping Human Research procedures that are not available outside the Human Research context, immediately contact the IRB chair and provide a written list of the currently enrolled subjects and why they will be harmed by stopping Human Research procedures. Human research that is determined to be exempt does not require continuing review. However, a "FORM HRP-212: Continuing/Final Review Progress Report should be submitted within 30 days of the completion of the study. How do I close out a study? Complete the FORM HRP-212: Continuing/Final Review Progress Report, attach all requested supplements, have the formed signed by the individuals listed in the form, and submit the documents to the PPHS office. Maintain electronic copies of all information submitted to the IRB. If you fail to submit a continuing/final review form to close out Human Research, you will be restricted from submitting new Human Research until the completed application has been received. If the continuing/final review application for closing out a Human Research study is not received by the date requested in the approval letter, you will be restricted from submitting new Human Research until the completed application is received. How long do I keep records? You are required to comply with Institutional record retention policy as outlined in the FACULTY HANDBOOK. Under federal regulations, you must maintain your Human Research records, including signed and dated consent documents, for three years after closing out the Human Research. Maintain HIPAA authorizations and other records related to HIPAA compliance for six years. If you are the sponsor-investigator of an IND or IDE, or if the Human Research is otherwise under the jurisdiction of the FDA, additional requirements for recordkeeping may be involved. Consult with the Compliance Department regarding your situation. If your Human Research has a financial sponsor, contact the sponsor before disposing of Human Research records. What if I need to use an unapproved drug or device in a life-threatening situation and there is no time for prior IRB review? Contact the Research Pharmacy immediately to discuss the situation. See the WORKSHEET HRP-317: Emergency Use of a Test Article in a Life Threatening Situation for the regulatory criteria allowing such a use and make sure these are followed. You will need to submit a report of the use to the IRB within five days of the use and an IRB application for initial review within 30 days. If you fail to submit the report within five days or the IRB application for initial review within 30
14 Investigator Manual Page 14 of 31 days, you will be restricted from submitting new Human Research until the report and IRB application for initial review have been received. Emergency use of an unapproved drug or device in a life-threatening situation without prior IRB review is research as defined by FDA, the individual getting the test article is a subject as defined by FDA, and therefore is governed by FDA regulations for IRB review and informed consent. Research Pharmacy has a form that they will provide to you to help them make the appropriate determination that the situation meets the criteria for an emergency use. Research Pharmacy also will provide you with a template information sheet to customize for the situation. Individuals getting an unapproved drug or device in a life-threatening situation without prior IRB review cannot be considered a subject as defined by DHHS and their results cannot be included in prospective research as that term is defined by DHHS. How do I get additional information and answers to questions? This document and the policies and procedures for the Program for Protection of Human Subjects are available on the IRB Web Site at If you have any questions or concerns, about the Human Research Protection Program, contact the PPHS office at: Phone: (212) If you have questions, concerns, complaints, allegations of undue influence, allegations or findings of non-compliance, or input regarding the Human Research Protection Program that cannot be addressed by contact the PPHS office, follow the directions in the HRP-101: HUMAN RESEARCH PROTECTION PROGRAM PLAN under Reporting and Management of Concerns.
15 Investigator Manual Page 15 of 31 Appendix A-1 Additional Requirements for DHHS-Regulated Research 1 1. When a subject decides to withdraw from a clinical trial, the investigator conducting the clinical trial should ask the subject to clarify whether the subject wishes to withdraw from all components of the trial or only from the primary interventional component of the trial. If the latter, research activities involving other components of the clinical trial, such as follow-up data collection activities, for which the subject previously gave consent may continue. The investigator should explain to the subject who wishes to withdraw the importance of obtaining follow-up safety data about the subject. 2. Investigators are allowed to retain and analyze already collected data relating to any subject who chooses to withdraw from a research study or whose participation is terminated by an investigator without regard to the subject s consent, provided such analysis falls within the scope of the analysis described in the IRB-approved protocol. This is the case even if that data includes identifiable private information about the subject. 3. For research not subject to regulation and review by FDA, investigators, in consultation with the funding agency, can choose to honor a research subject s request that the investigator destroy the subject s data or that the investigator exclude the subject s data from any analysis. 4. When seeking the informed consent of subjects, investigators should explain whether already collected data about the subjects will be retained and analyzed even if the subjects choose to withdraw from the research. 1
16 Investigator Manual Page 16 of 31 Appendix A-2 Additional Requirements for FDA-Regulated Research 1. When a subject withdraws from a study: 2 a. The data collected on the subject to the point of withdrawal remains part of the study database and may not be removed. b. An investigator may ask a subject who is withdrawing whether the subject wishes to provide continued follow-up and further data collection subsequent to their withdrawal from the interventional portion of the study. Under this circumstance, the discussion with the subject would distinguish between study-related interventions and continued follow-up of associated clinical outcome information, such as medical course or laboratory results obtained through non-invasive chart review, and address the maintenance of privacy and confidentiality of the subject s information. c. If a subject withdraws from the interventional portion of the study, but agrees to continued follow-up of associated clinical outcome information as described in the previous bullet, the investigator must obtain the subject s informed consent for this limited participation in the study (assuming such a situation was not described in the original informed consent form). IRB approval of informed consent documents is required. d. If a subject withdraws from the interventional portion of a study and does not consent to continued follow-up of associated clinical outcome information, the investigator must not access for purposes related to the study the subject s medical record or other confidential records requiring the subject s consent. e. An investigator may review study data related to the subject collected prior to the subject s withdrawal from the study, and may consult public records, such as those establishing survival status. 2. For FDA-regulated research involving investigational drugs: a. Investigators must abide by FDA restrictions on promotion of investigational drugs: 3 i. An investigator, or any person acting on behalf of an investigator, must not represent in a promotional context that an investigational new drug is safe or effective for the purposes for which it is under investigation or otherwise promote the drug. ii. This provision is not intended to restrict the full exchange of scientific information concerning the drug, including dissemination of scientific findings in scientific or lay media. Rather, its intent is to restrict promotional claims of safety or effectiveness of the drug for a use for which it is under investigation and to preclude commercialization of the drug before it is approved for commercial distribution. iii. An investigator must not commercially distribute or test market an investigational new drug. b. Follow FDA requirements for general responsibilities of investigators 4 i. An investigator is responsible for ensuring that an investigation is conducted according to the signed investigator statement, the investigational plan, and applicable regulations; for protecting the rights, safety, and welfare of subjects under the investigator's care; and for the control of drugs under investigation
17 Investigator Manual Page 17 of 31 ii. An investigator must, in accordance with the provisions of 21 CFR 50, obtain the informed consent of each human subject to whom the drug is administered, except as provided in 21 CFR or of this chapter. iii. Additional specific responsibilities of clinical investigators are set forth in this part and in 21 CFR 50 and 21 CFR 56. c. Follow FDA requirements for control of the investigational drug 5 i. An investigator must administer the drug only to subjects under the investigator's personal supervision or under the supervision of a sub-investigator responsible to the investigator. ii. The investigator must not supply the investigational drug to any person not authorized under this part to receive it. d. Follow FDA requirements for investigator recordkeeping and record retention 6 i. Disposition of drug: 1. An investigator is required to maintain adequate records of the disposition of the drug, including dates, quantity, and use by subjects. 2. If the investigation is terminated, suspended, discontinued, or completed, the investigator must return the unused supplies of the drug to the sponsor, or otherwise provide for disposition of the unused supplies of the drug under 21 CFR ii. Case histories. 1. An investigator is required to prepare and maintain adequate and accurate case histories that record all observations and other data pertinent to the investigation on each individual administered the investigational drug or employed as a control in the investigation. 2. Case histories include the case report forms and supporting data including, for example, signed and dated consent forms and medical records including, for example, progress notes of the physician, the individual's hospital charts, and the nurses' notes. The case history for each individual must document that informed consent was obtained prior to participation in the study. iii. Record retention: An investigator must retain required records for a period of 2 years following the date a marketing application is approved for the drug for the indication for which it is being investigated; or, if no application is to be filed or if the application is not approved for such indication, until 2 years after the investigation is discontinued and FDA is notified. e. Follow FDA requirements for investigator reports 7 i. Progress reports: The investigator must furnish all reports to the sponsor of the drug who is responsible for collecting and evaluating the results obtained. ii. Safety reports: An investigator must promptly report to the sponsor any adverse effect that may reasonably be regarded as caused by, or probably caused by, the drug. If the adverse effect is alarming, the investigator must report the adverse effect immediately. iii. Final report: An investigator must provide the sponsor with an adequate report shortly after completion of the investigator's participation in the investigation. iv. Financial disclosure reports:
18 Investigator Manual Page 18 of The clinical investigator must provide the sponsor with sufficient accurate financial information to allow an applicant to submit complete and accurate certification or disclosure statements as required under 21 CFR The clinical investigator must promptly update this information if any relevant changes occur during the course of the investigation and for 1 year following the completion of the study. f. Follow FDA requirements for assurance of IRB review 8 i. An investigator must assure that an IRB that complies with the requirements set forth in 21 CFR 56 will be responsible for the initial and continuing review and approval of the proposed clinical study. ii. The investigator must also assure that he or she will promptly report to the IRB all changes in the research activity and all unanticipated problems involving risk to human subjects or others, and that he or she will not make any changes in the research without IRB approval, except where necessary to eliminate apparent immediate hazards to human subjects. g. Follow FDA requirements for inspection of investigator's records and reports 9 i. An investigator must upon request from any properly authorized officer or employee of FDA, at reasonable times, permit such officer or employee to have access to, and copy and verify any records or reports made by the investigator pursuant to ii. The investigator is not required to divulge subject names unless the records of particular individuals require a more detailed study of the cases, or unless there is reason to believe that the records do not represent actual case studies, or do not represent actual results obtained. h. Follow FDA requirements for handling of controlled substances 10 i. If the investigational drug is subject to the Controlled Substances Act, the investigator must take adequate precautions, including storage of the investigational drug in a securely locked, substantially constructed cabinet, or other securely locked, substantially constructed enclosure, access to which is limited, to prevent theft or diversion of the substance into illegal channels of distribution. 3. For FDA-regulated research involving investigational devices: a. General responsibilities of investigators. 11 i. An investigator is responsible for ensuring that an investigation is conducted according to the signed agreement, the investigational plan and applicable FDA regulations, for protecting the rights, safety, and welfare of subjects under the investigator's care, and for the control of devices under investigation. An investigator also is responsible for ensuring that informed consent is obtained in accordance with 21 CFR 50. b. Specific responsibilities of investigators 12 i. Awaiting approval: An investigator may determine whether potential subjects would be interested in participating in an investigation, but must not request the written informed consent of any subject to participate, and must not allow any subject to participate before obtaining IRB and FDA approval
19 Investigator Manual Page 19 of 31 ii. Compliance: An investigator must conduct an investigation in accordance with the signed agreement with the sponsor, the investigational plan, and other applicable FDA regulations, and any conditions of approval imposed by an IRB or FDA. iii. Supervising device use: An investigator must permit an investigational device to be used only with subjects under the investigator's supervision. An investigator must not supply an investigational device to any person not authorized to receive it. iv. Financial disclosure: 1. A clinical investigator must disclose to the sponsor sufficient accurate financial information to allow the applicant to submit complete and accurate certification or disclosure statements required under 21 CFR The investigator must promptly update this information if any relevant changes occur during the course of the investigation and for 1 year following completion of the study. v. Disposing of device: Upon completion or termination of a clinical investigation or the investigator's part of an investigation, or at the sponsor's request, an investigator must return to the sponsor any remaining supply of the device or otherwise dispose of the device as the sponsor directs. c. Maintain the following accurate, complete, and current records relating to the investigator's participation in an investigation: 13 i. All correspondence with another investigator, an IRB, the sponsor, a monitor, or FDA, including required reports. ii. Records of receipt, use or disposition of a device that relate to: 1. The type and quantity of the device, the dates of its receipt, and the batch number or code mark. 2. The names of all persons who received, used, or disposed of each device. 3. Why and how many units of the device have been returned to the sponsor, repaired, or otherwise disposed of. iii. Records of each subject's case history and exposure to the device. Case histories include the case report forms and supporting data including, for example, signed and dated consent forms and medical records including, for example, progress notes of the physician, the individual's hospital charts, and the nurses' notes. Such records must include: 1. Documents evidencing informed consent and, for any use of a device by the investigator without informed consent, any written concurrence of a licensed physician and a brief description of the circumstances justifying the failure to obtain informed consent. 2. Documentation that informed consent was obtained prior to participation in the study. 3. All relevant observations, including records concerning adverse device effects (whether anticipated or unanticipated), information and data on the condition of each subject upon entering, and during the course of, the investigation, including information about relevant previous medical history and the results of all diagnostic tests. 4. A record of the exposure of each subject to the investigational device, including the date and time of each use, and any other therapy. 13
Investigator Manual. Human Subjects Protection Program
Human Subjects Protection Program HRP-103, Revised June 1, 2015 HRP-103 06/01/2015 2 of 33 Table of Contents Scope... 3 What is the purpose of this manual?... 3 What is Human Research?... 3 What is the
More informationInvestigator Manual HRP-103
HRP-103 Revised October 04, 2016 Table of Contents 1. Introduction... 3 A. Scope... 3 B. Purpose of this manual... 3 C. Where to get additional information and answers to questions... 3 E. Human Research
More informationHuman Research Protection Program. Investigator Manual
Human Research Protection Program Revised July 7, 2014 HRP-910 7/7/2014 2 of 10 Table of Contents What is the purpose of this manual?... 3 What is Human Research?... 3 What is the Human Research Protection
More informationStandard Operating Procedures Guidelines for Good Clinical Practice
SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA
More informationHuman Research Protection Program. Plan
Human Research Protection Program Plan Dated: September 4, 2014 HRP-101 9/4/2014 2 of 14 Table of Contents Scope... 3 Purpose... 3 Definitions... 3 Agent... 3 Clinical Trial... 3 Engaged in Human Research...
More informationVCU Faculty Held IND and IDE Procedure Handbook
VCU Faculty Held IND and IDE Procedure Handbook Contents A. Introduction... 3 B. Purpose of Institutional Oversight... 3 C. Applicability... 4 D. University Oversight of Clinical Investigations Being Conducted
More informationRules of Human Experimentation
Rules of Human Experimentation Elaine Larson CUMC IRB Chair Associate Dean for Research, School of Nursing Professor of Epidemiology, Mailman School of Public Health Oversight for Human Research Office
More informationInstitutional Biosafety Committee
Northern Illinois University Institutional Biosafety Committee Policy Office of Research Compliance, Integrity and Safety 2017 Northern Illinois University Institutional Biosafety Committee Purpose...
More informationGW Policy on Human Research Protection Program
GW Policy on Human Research Protection Program 1. PURPOSE 1.1. This policy establishes the [Organization] s Human Research Protection Program (HRPP) and its commitment to protect the rights and welfare
More informationEmbryonic Stem Cell Research Oversight Committee (ESCRO) Application Form
Embryonic Stem Cell Research Oversight Committee (ESCRO) Application Form A. Demographic Information Date of Submission: Reason for Submission: New Project Response to Comments Reconsideration Disapproval
More informationHuman Research Protection Program Compliance Plan
Human Research Protection Program Compliance Plan May 1, 2016 Human Research Protections Program e 1313 21 st Ave. South, Room 504, Nashville, Tennessee 37232 4315 e phone 615-322-2918 e fax 615-343-2648
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationFDA-Regulated Research
Chapter 18: FDA-Regulated Research Chapter Contents 18.1 FDA-Regulated Research 18.2 Investigational Drugs 18.3 Investigational Medical Devices 18.4 Sponsor-Investigators 18.5 Humanitarian Use Devices
More informationEthics Committees/IRBs Today: Challenges for Efficiency and Quality
Marjorie A. Speers, Ph.D. President and CEO Ethics Committees/IRBs Today: Challenges for Efficiency and Quality Copyright 2013 AAHRPP All rights reserved Goal Clinical Research Globally Access to patients
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
SOP #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional responsibilities
More informationFDA Sponsor and Investigator Responsibility Checklist
FDA Sponsor and Investigator Responsibility Checklist Principal Investigator: Study Name: CPHS #: IND/IDE #: Name of IND/IDE holder: The following checklist is created based on the Sponsor and Investigator
More informationTip Sheet 17: Review of Research by the Expedited Procedure
Tip Sheet 17: Review of Research by the Expedited Procedure Related Accreditation Elements: II.2.E. Policies and procedures should describe review using the expedited procedure, when an expedited procedure
More informationAPPLICATION INSTRUCTIONS INSTITUTIONAL REVIEW BOARD. Revised January 2010 Page 1
APPLICATION INSTRUCTIONS INSTITUTIONAL REVIEW BOARD Revised January 2010 Page 1 The IRB Proposal Includes: 1. All documents, other than the informed consent form, should be understandable to an informed
More informationKathy Weil Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological Health US Food and Drug Administration
Kathy Weil Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological Health US Food and Drug Administration Kathy.Weil@fda.hhs.gov Follow the protocol and IDE regulations
More informationExternal IRB Review What Does it Mean for Your Institution
External IRB Review What Does it Mean for Your Institution Wesley G Byerly, Pharm.D. Associate Vice President for Research Integrity and Regulatory Affairs University of Connecticut and UCONN Health HCCA
More informationOutline of Discussion
This final rule is intended to better protect human subjects involved in research, while facilitating valuable research and reducing burden, delay, and ambiguity for investigators. These revisions are
More informationObjectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National
More informationQuality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework
1 Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework Mandy Morneault Research Compliance Monitor University of Washington Institute of Translational Health
More informationExpanded Access. to Investigational Drugs & Biologics. for Treatment Use
SJMHS Research Compliance Office Guidance Document Expanded Access to Investigational Drugs & Biologics for Treatment Use May 2015 1 Expanded Access to Investigational Drugs & Biologics for Treatment Use
More informationRECRUITING OF AND ADVERTISING FOR SUBJECTS
1. POLICY Steering Committee approved 9/19/11 The informed consent process begins when a potential human research subject first learns of a study, which is usually accomplished through recruitment efforts.
More informationInstitutional Biosafety Committee. Policies and Procedures
Institutional Biosafety Committee Policies and Procedures September 2011 CONTENTS 1. INTRODUCTION 1.1 UNLV Institutional Biosafety Committee Roles and Responsibilities 1.2 The Foundation for IBC Review:
More informationStreamlining IRB Procedures for Expanded Access
Streamlining IRB Procedures for Expanded Access Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation Richard Klein Director, FDA Patient Liaison Program Office of Health and Constituent Affairs
More informationGood Clinical Practice
Clinical Site Monitoring DMID/ICSSC 10/7/08 1 Monitoring ICH E6 5.18.1 The purpose of monitoring is to ensure that: The rights and well-being of subjects are being protected The data are accurate, complete
More informationStanford University IRB Guidance On Data and Tissue Repositories
Stanford University IRB Guidance On Data and Tissue Repositories Databases, registries (data banks), and repositories (tissue banks) all involve the collection and storage of information and/or biological
More informationFlorida State University Policy 7-IRB-
Florida State University Policy 7-IRB- Title of Policy: Institutional Review Board Jurisdiction/Applicability Responsible Executive: Gary K. Ostrander Approving Official: Gary K. Ostrander Effective Date:
More informationEIGHT BASIC ELEMENTS OF INFORMED CONSENT
1/6 This guidance addresses: o Eight Basic elements of informed consent o Additional elements of informed consent o Other information required by the IRB EIGHT BASIC ELEMENTS OF INFORMED CONSENT Required
More informationInvestigator-Initiated INDs
Investigator-Initiated INDs Marjorie Small, RN, CCRC Office of Clinical Research 23 May 2011 PPHS/IRB Research Grand Rounds Outline of Presentation I. What is an IND? II. Code of Federal Regulations III.
More informationIntroduction to Clinical Research
Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that
More informationINVESTIGATOR HANDBOOK
INVESTIGATOR HANDBOOK INVESTIGATOR HANDBOOK Table of Contents MISSION... 3 FIRST TIME SUBMISSION... 3 EDUCATIONAL REQUIREMENTS... 3 PRINCIPAL INVESTIGATOR NEW STUDY SUBMISSIONS... 4 VULNERABLE POPULATIONS...
More informationClinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014
Clinical Trials and the Code of Federal Regulations Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 The Development of Regulations 1906: Food and Drugs Act
More informationSITE SUBMISSION FORM (SINGLE SITE)
*We accept study submissions by email, fax or mail. 1. STUDY INFORMATION A. Sponsor: Protocol.: Study Title: B. Study Type: Drug, Biologic or Dietary Supplement (please complete section C., then proceed
More informationTOP 10 INVESTIGATOR RESPONSIBILITIES WHEN CONDUCTING HUMAN SUBJECTS RESEARCH
Investigators Responsibility #1: Design and Implement Ethical Research Consistent with the Three Ethical Principles Delineated in The Belmont Report. The Belmont Report: Three Basic Ethical Principles:
More informationPROTOCOL DRAFTING GUIDE
MUHC Research Ethics Board (Neurosciences & Psychiatry) Comité d éthique de la recherche du MUHC (Neurosciences & psychiatrie) PROTOCOL DRAFTING GUIDE LIST OF ITEMS TO BE INCLUDED IN A PROTOCL FOR RESEARCH
More informationInstitutional Biosafety Committee
Northern Illinois University Institutional Biosafety Committee Policy Office of Research Compliance and Integrity 5/9/2013 Northern Illinois University Institutional Biosafety Committee Purpose... 1 Scope...
More informationDARTMOUTH COLLEGE BIOLOGICAL SAFETY PROGRAM Institutional Biosafety Committee Subcommittee for Clinical Gene Transfer
INSTITUTIONAL BIOSAFETY COMMITTEE SUBCOMMITTEE FOR CLINICAL GENE TRANSFER (IBC-SCGT) CHARTER Approval Date: 12.18.14 Version: 1 DARTMOUTH COLLEGE BIOLOGICAL SAFETY PROGRAM Institutional Biosafety Committee
More information\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management
Five Content Areas Percent of Scored Test Items (Range) in Each Area This table shows the percent of scored test questions that are included in each major content area. Five Content Areas Ethical Principles
More informationQuality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits
Quality Assurance QA 601.01 STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick
More informationDRUG ORDERING AND MAINTENANCE
AND MAINTENANCE Disclaimer: Please note that the instructions provided in this chapter mainly apply to agents provided by the Pharmaceutical Management Branch (PMB), of Cancer Therapy Evaluation Program
More informationProtection of Research Participants: The IRB Process and the Winds of Change
Protection of Research Participants: The IRB Process and the Winds of Change Ethics in Patient-Oriented Research October 12, 2011 Sharon Friend Director, OHRPP Overview Charge and Function of the IRB Quick
More informationStudy Files and Filing
Study Files and Filing The current version of all Hillingdon Hospital R&D Guidance Documents and Standard Operating Procedures are available from the R&D Intranet and Internet sites: www.ths.nhs.uk/departments/research/research.htm
More informationCANCER CENTER SCIENTIFIC REVIEW COMMITTEE
CANCER CENTER SCIENTIFIC REVIEW COMMITTEE The Clinical Scientific Review Committee (SRC) at The Medical College of Wisconsin Cancer Center plays a vital role in protocol review and monitoring to ensure
More informationINVESTIGATIONAL DEVICE EXEMPTION APPLICATION. IDE Title (if title being used)
INVESTIGATIONAL DEVICE EXEMPTION APPLICATION IDE Title (if title being used) Name of Sponsor Investigator, MD X Professor, Department Icahn School of Medicine at Mount Sinai Date of Submission Form version
More informationExpanded Access and the Individual Patient IND
Expanded Access and the Individual Patient IND Research Wednesdays April 26, 2017 Erika Segear Johnson, PhD, RAC Associate Director of Regulatory Affairs Office of Regulatory Affairs and Quality Office
More informationWhat s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance
Vol. 9, No. 2, February 2013 Happy Trials to You What s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance Reprinted from the Guide to Good Clinical Practice with permission of Thompson Publishing
More informationUniversity of New Mexico Health Sciences Center Office of Research Policy for the Oversight of Human Tissue in Research
1. Applicability This policy applies to all tissues collected from volunteers and from nonliving human subjects for the purpose of research. Oversight of this policy and these tissues are the responsibility
More informationPreparing for a United States Food and Drug Administration (FDA) Inspection: VOICE
Preparing for a United States Food and Drug Administration (FDA) Inspection: VOICE This project has been funded in whole or in part with Federal funds from the Division of AIDS (DAIDS), National Institute
More informationRadiation - Florida Department of Health Institutional Review Board
500-26 Radiation 500-26 Radiation - Florida Department of Health Institutional Review Board Protocol title: Researcher: Application contact: For questions, concerns, to provide input, or request a consultation,
More informationIRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010
IRB-GCP and Timelines Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October 11-14 th, 2010 1 Factors that affect Timelines Finalized Protocol Finalized
More informationApplicability of US Regulations to Canadian Research
Applicability of US Regulations to Canadian Research Mary Kate Needler Capital District Health Authority Halifax, Nova Scotia, Canada N2 Stakeholder Meeting August 18, 2014 MK s Conventions: 1. US Regulation
More informationEmbryonic Stem Cell Research Oversight (ESCRO) Committee. Policies and Procedures
University of California, Los Angeles Embryonic Stem Cell Research Oversight (ESCRO) Committee TABLE OF CONTENTS Section Page 1.0 Purpose... 2 2.0 Authority... 2 3.0 Function... 2 4.0 Review... 2 4.1 Review
More informationNORTHEASTERN UNIVERSITY INSTITUTIONAL BIOSAFETY COMMITTEE CHARTER
NORTHEASTERN UNIVERSITY INSTITUTIONAL BIOSAFETY COMMITTEE CHARTER Date Approved: 7/11/17 Last Revision Date: 7/11/17 Introduction I. Purpose Northeastern University s (NU) Institutional Biosafety Committee
More informationStudy Start-Up SS STANDARD OPERATING PROCEDURE FOR Investigator Selection
Effective date of version: April 01, 2012 Study Start-Up SS 202.00 STANDARD OPERATING PROCEDURE FOR Investigator Selection Approval: Nancy M. Paris, MS, FACHE President and CEO 08 March 2012 (Signature
More informationClinical Trials Management for Molecular Diagnostics. April 2016
Clinical Trials Management for Molecular Diagnostics April 2016 Clinical Operations Responsibilities Accrue samples that have proper informed consent for use Retrospective cohorts Remnant samples Prospective
More informationH-20 Page 1 of 5. Institutional Review Board Policy Manual HUMANITARIAN USE DEVICE (HUD) REQUIREMENTS
H-20 Page 1 of 5 Institutional Review Board Policy Manual HUMANITARIAN USE DEVICE (HUD) REQUIREMENTS PURPOSE: To describe the requirements for McLeod Health IRB review of Humanitarian Use Devices (HUD).
More informationSource Documents and Regulatory Binders October 6, 2016
Source Documents and Regulatory Binders October 6, 2016 Lisa Wilson, Regulatory Lead, Clinical Trials Office and Mark Alger, CRC, Clinical Trials Office Essential Documents AKA: the stuff in the Reg Binder
More informationGCP Convergence Improves Transportability of Medical Device Clinical Data
GCP Convergence Improves Transportability of Medical Device Clinical Data By Harmonization-by-Doing Working Group 4 The safety, performance and effectiveness of medical devices are often evaluated by well-controlled
More informationHuman Research Protections Program Policies and Standard Operating Procedures
Human Research Protections Program Policies and Standard Operating Procedures Version Date: April 2018 Presbyterian Healthcare Services Human Research Protections Office and Institutional Review Board
More informationREGULATORY ISSUES: HOW TO APPLY FOR AN IND. Penny Jester and Maaike Everts
REGULATORY ISSUES: HOW TO APPLY FOR AN IND Penny Jester and Maaike Everts Outline 2 What is the purpose of an IND? What types of INDs are there? When do you need one? How do you apply for one? How do you
More informationRochester Institute of Technology Institutional Biosafety Committee (IBC) Guidelines for Committee Authority, Structure and Responsibilities
1. Purpose The purpose of this document is to provide details of the responsibilities, scope of authority and structure of the. 2. Mission The mission of the Institutional Biosafety Committee is to: 2.1.
More informationHuman Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents
Guidance for s Regulatory File Essential s All principal investigators must maintain a regulatory binder or file system, which contains all study documentation. These records may be reviewed at the time
More informationDATA SHARING AGREEMENT
DATA SHARING AGREEMENT Effective Date: This Data Sharing Agreement ( Agreement ) is effective as of the Effective Date between EMD Serono, One Technology Place, Rockland, MA 02370 and Name ( Institution
More information3. Human Biomedical Research. Defining Human Biomedical Research
PART B: SECTION III: HUMAN BIOMEDICAL RESEARCH HUMAN BIOMEDICAL RESEARCH 3. Human Biomedical Research Defining Human Biomedical Research 3.1. In this section, we consider what kinds of human biomedical
More informationGOOD CLINICAL PRACTICE (GCP) Series Catalog
GOOD CLINICAL PRACTICE (GCP) Series Catalog CITI Program s GCP series consists of three basic courses and three refresher courses. The basic courses include: GCP for Clinical Trials with Investigational
More informationWhat is an IRB (Institutional Review Board)?
What is an IRB (Institutional Review Board)? The Belmont Report The Belmont Report on the Ethical Principles and Guidelines for the Protection of Human Subjects of Research was prepared by the National
More informationA notice on the issuance of drug clinical trials, ethical review of the guiding principles
药物临床试验伦理审查工作指导原侧.doc 的翻译 A notice on the issuance of drug clinical trials, ethical review of the guiding principles State Food and Drug Administration Note [2010] No. 436 November 2, 2010 Release A notice
More informationThe Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Determination of IND/IDE Requirement
Page: 1 of 8 I. PURPOSE II. III. IV. The purpose of this Standard Operating Procedure is to delineate when an investigator must obtain an Investigational New Drug (IND) or Investigational Device Exemption
More information07/30/2013. Record of Revisions IRB Page 1 of 17
Current Protocol Version 7.1 (Continuing Review) Approved July 30, 2013 Version 7.1 (Amendment) September 6, 2012 Version 7.0 (Continuing Review) July 30, 2012 Version 6.0 (Continuing Review) July 30,
More informationSTUDY REQUEST FORM AND TRAQ DSS FORM
Research Road Map April 2017 In This Issue Pharmacy Services for Research Study Request Form and TRAQ DSS FORM Management of Investigational Drugs Pharmacy Standard Operating Procedures IDS Team Qualifications
More information2 : self-directing freedom and especially moral independence 3 : a self-governing state
A Adverse Effect Adverse Event AE Amendment Approve Approve Pending Assent Assurance Authorization Autonomy Unanticipated problem or unfavorable symptom or disease occurring during a clinical study, though
More informationThe Revised Common Rule. Ann Johnson, PhD, MPH IRB Director University of Utah
The Revised Common Rule Ann Johnson, PhD, MPH IRB Director University of Utah Objectives Describe the Changes that Affect the UU IRB What does this mean for ERICA? UPDATE: The postponement to January 2019
More informationGCP Basics - refresher
p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History
More informationOffice of Graduate and Professional Studies
Reset Form Print Form Office of Graduate and Professional Studies PROPOSAL APPROVAL FORM FOR THESIS, DISSERTATION, OR RECORD OF STUDY Full proposal should be attached This form must be approved by OGAPS
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL STUDY PROTOCOL CHAPTER 14 REVISED: OCTOBER 2015
THE STUDY PROTOCOL The study protocol is a written document detailing how a clinical trial is conducted. The elements of a protocol include: 1. Trial design and organization; 2. Study objectives; 3. Background
More informationVanessa Laroche, CCRC, CCRA, CIP, CQA Quality Assurance Specialist Technical Resources International (TRI), Inc.
December 8, 2016 C2012 Web Seminar Series Identifying and Reporting Protocol Deviations Vanessa Laroche, CCRC, CCRA, CIP, CQA Quality Assurance Specialist Technical Resources International (TRI), Inc.
More informationSOUTH DAKOTA STATE UNIVERSITY Policy and Procedure Manual
Office/Contact: Office of Research Assurance and Sponsored Programs Source: NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) Link: https://osp.od.nih.gov/biotechnology/nih-guidelines/
More informationPHARMACY, MEDICINES & POISONS BOARD
PHARMACY, MEDICINES & POISONS BOARD PHARMACY GUIDELINES FOR INVESTIGATIONAL DRUGS A. Purpose These guidelines are principally derived and adapted from guidelines from various sources within the SADC region.
More informationHuman Research Protection Program Guidance for Human Research Determination
Human Research Protection Program Guidance for Human Research Determination I.1.A The sole purpose of the Institutional Review Board (IRB), as defined in federal statutes, is the protection of human subjects
More informationHospital Authority (HA) Guide on Research Ethics (for Study Site & Research Ethics Committee)
Page 1 of 8 Hospital Authority (HA) Guide on Research Ethics (for Study Site & Version Effective Date 2 01/02/2015 Document Number HAHO-CE&TM-HA REC Author HA Head Office Steering Committee on Research
More informationMARKEY CANCER CENTER CLINICAL RESEARCH ORGANIZATION STANDARD OPERATING PROCEDURES SOP No.: MCCCRO-P
Page 1 of 5 MARKEY CANCER CENTER CLINICAL RESEARCH ORGANIZATION STANDARD OPERATING PROCEDURES SOP No.: Title: Protocol Review and Monitoring Committee Revision: N/A Revision Date: N/A Functional and Administrative
More information1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.
1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended
More informationInstitutional Review Board Compliance Elizabeth City State University
Institutional Review Board Compliance Elizabeth City State University Michelle Moore, MBA Research Compliance Officer/IRB Administrator Office of Sponsored Programs, Contracts & Grants 110 McLendon Hall
More informationGenentech, Inc., its research partners, collaborators, assignees, licensees or designees. Invitation to Participate
CONSENT AND RESEARCH AUTHORIZATION TO DONATE BLOOD AND TISSUE SAMPLES FOR FUTURE RESEARCH PURPOSES YALE UNIVERSITY SCHOOL OF MEDICINE YALE-NEW HAVEN HOSPITAL 200 FR. 4 Study Title: An Open-Label, Phase
More informationThe University of Texas Southwestern Medical Center Institutional Review Board Oversight Audit. Internal Audit Report 14:07
Office of Internal Audit The University of Texas Southwestern Medical Center Institutional Review Board Oversight Audit Internal Audit Report 14:07 November 17, 2014 Table of Contents I. Executive Summary
More informationSource And Regulatory Documentation for DMID Clinical Studies
Source And Regulatory Documentation for DMID Clinical Studies Walt Jones RN, MPH Nurse Consultant Clinical Monitoring Coordinator OCRA, DMID, NIAID November, 2007 Source Data Defined All information in
More informationINVESTIGATIONAL DRUG MANAGEMENT OVERVIEW
NORTHWELL HEALTH OFFICE OF RESEARCH COMPLIANCE STUDY FEASIBILITY AND APPROVAL Where can I learn about the investigational drug? Protocol Investigator s brochure Product insert or prescribing information
More informationUniversity of Virginia Cancer Center
University of Virginia Cancer Center Data and Safety Monitoring Plan for Clinical Research March 18, 2016 Approved: National Cancer Institute April 14 th, 2016 Table of Contents 1. Introduction... 3 2.
More informationPARTNERS HUMAN RESEARCH COMMITTEE. Human Tissues: Brief Primer on Research Use and Requirement for Partners IRB Review
PARTNERS HUMAN RESEARCH COMMITTEE Human Tissues: Brief Primer on Research Use and Requirement for Partners IRB Review For the purposes of this Primer, tissue is defined as any biological specimen obtained
More informationThe Bank of Elk River: Digital Wallet Terms and Conditions
The Bank of Elk River: Digital Wallet Terms and Conditions These Terms of Use ("Terms") govern your use of any eligible debit card issued by The Bank of Elk River (a "Payment Card") when you add, attempt
More informationResearch Involving Human Data or Specimens
Page 1 of 5 Research Involving Human Data or Specimens Introduction: The Office for Human Research Protections has issued guidance on research involving coded private information or human biological specimens.
More informationKANSAS STATE UNIVERSITY INSTITUTIONAL BIOSAFETY COMMITTEE STANDARD OPERATING PROCEDURES
KANSAS STATE UNIVERSITY INSTITUTIONAL BIOSAFETY COMMITTEE STANDARD OPERATING PROCEDURES I. INTRODUCTION The Kansas State University (K State) Institutional Biosafety Committee, hereafter referred to as
More informationRecommendations for Strengthening the Investigator Site Community
Recommendations for Strengthening the Investigator Site Community October 2017 CTTI MISSION: To develop and drive adoption of practices that will increase the quality and efficiency of clinical trials
More informationSUBJECT: INSTITUTIONAL REVIEW BOARD (IRB) - HUMANITARIAN USE DEVICES
This policy applies to the following entity(s): Children s Hospital of Wisconsin Children s Hospital and Health System, Inc. Administrative Policy and Procedure Children s Research Institute SUBJECT: INSTITUTIONAL
More informationVolunteering for Clinical Trials
Volunteering for Clinical Trials Volunteering for Clinical Trials When considering volunteering for a clinical trial, it is important to make an informed decision. Below are answers to frequently asked
More informationRESEARCH PERFORMANCE SITES AND COLLABORATIVE OFF-SITE RESEARCH
1. Overview RESEARCH PERFORMANCE SITES AND COLLABORATIVE OFF-SITE RESEARCH The ethical and regulatory requirements of The Ohio State University Human Research Protection Program (HRPP) apply to all research
More informationSUBSTANCE ABUSE POLICY
SUBSTANCE ABUSE POLICY The Company has a vital interest in the health and welfare of its employees. The misuse and abuse of alcohol and drugs by employees pose serious threats to the safety and health
More information